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Background 
Early screening of type 2 diabetes mellitus (DM), a hyperglycemia phenotype associated condition, is essential for preventive treatment and 
effective delay of diabetes clinical complications [1]. However, testing for hyperglycemia phenotype (fasting blood glucose > 110 mg/dl) often 
requires invasive and painful blood testing, limiting its large-scale usefulness. To overcome this constraint salivary glucose assays have recently 
being applied with the purpose of screening hyperglycemia and type 2 DM [2]. Literature results regarding glycemia and salivary glucose 
relationship in diabetics or in healthy individuals are controversial. On the other hand, to the best of our knowledge no cross-validation has been 
done on type 2 DM / hyperglycemia detection models based on salivary glucose. We have performed a systematic review and meta-analysis on 
previous studies and cross-validated a type 2 DM / hyperglycemia phenotype predictor model based on salivary glucose. 
  
Experimental Methods   
• Meta-analysis results show a significant increase of salivary 
glucose concentration  on type 2 DM individuals (Hedge's g  > 1).  
 
• The fitted models show a good accuracy within the training 
sample for predicting both hyperglycemia (81,0%) and type 2 DM 
(84,5%), while in the external data cross-validation the prediction 
accuracy was lower: hyperglycemia (68,1%) and type 2 DM 
(65,5%).  
Conclusions 
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We conducted a meta-analysis 
of peer-reviewed published 
articles that reported data 
regarding mean salivary glucose 
levels for type 2 DM and non-
diabetic individuals combined 
with our own results [3]. 
Furthermore, we used our blood 
and salivary glucose data from 
type 2 diabetics and healthy 
individuals to build type 2 DM / 
hyperglycemia phenotype 
logistic prediction models. These 
models were cross-validated 
against external data (Brazil and 
India) and accuracy was 
evaluated through ROC curve 
analysis. 
  
Figure 2 - Subgroup forest plot of type 2 DM mean salivary glucose levels studies. Studies have been grouped according to the type 2 DM 
group allocation: with or without subsets. Hedge's g (standardized mean difference) effect size estimates have been calculated with 95% 
confidence intervals and are shown in the figure. Area of squares represents sample size, continuous horizontal lines and diamonds width 
represents 95% confidence interval. Yellow diamonds center indicates the subgroup pooled estimates while the blue diamond center and 
the vertical red dotted line both point to the overall pooled estimate. 
  
•    Salivary glucose has potential to be used as a hyperglycemia phenotype biomarker combined with other salivary biomarkers and 
associated with sensitive portable technology.  
 
•    Salivary glucose don't show enough cross-validation performance to be used as a hyperglycemia phenotype global biomarker and 
therefore predictions should be based on region specific models. 
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Figure 1 - Flow of study selection for mean salivary glucose levels. *Studies were excluded unless contained salivary glucose data (means, 
standard deviations and sample size) obtained from strictly diabetes mellitus type 2 patients and non-diabetic controls unstimulated whole 
saliva collected after a minimum fast period of 2 hours. Were also excluded if the full-text article were not available and the author(s) failed 
in sending a copy after contact request or failed in giving back supplementary required data inexistent in the original article. Records 
containing data already published in other article were also excluded. 
 
  
Results 
Table 1 – Predictive logistic models accuracy (%). * Portuguese training dataset; ** External cross-validation dataset (Brazil 
and India data)  
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